Treatment of Diabetes Mellitus in Elderly Patients

First-Line Options

For an elderly patient with diabetes mellitus and hyperglycemia who declines metformin and insulin, a DPP-4 inhibitor, such as linagliptin, is the treatment of choice due to its favorable safety profile, minimal hypoglycemia risk, and effectiveness in elderly patients 1, 2
DPP-4 inhibitors have few side effects and minimal risk of hypoglycemia, making them particularly suitable for elderly patients 1
Among DPP-4 inhibitors, linagliptin may be especially appropriate as it can be used as an alternative to metformin in older adults with low GFR without dose adjustment 2
These medications are useful in older adults with mild hyperglycemia or with high risk of hypoglycemia 2

When selecting glucose-lowering medications for older adults, consider individual comorbidities, such as CKD, ASCVD, low body weight, and risk of dehydration 1
Medication cost may be an important consideration, as older adults tend to be on many medications and often live on fixed incomes 2

GLP-1 receptor agonists can be effective for glycemic control and may provide additional benefits for cardiovascular health 3
Consider GLP-1 receptor agonists if the patient has cardiovascular disease or would benefit from weight loss 3

Sulfonylureas, such as glipizide, are preferred over longer-acting ones like glyburide, which should be avoided in older adults due to hypoglycemia risk 2, 4
Many antimicrobials interact with sulfonylureas, increasing hypoglycemia risk 1
Thiazolidinediones, such as pioglitazone, should be used very cautiously, if at all, in older adults due to risks of fluid retention, weight gain, heart failure, osteoporosis, falls, fractures, and macular edema 2

Less stringent glycemic targets, such as HbA1c around 8.0%, are appropriate for frail older adults, those with limited life expectancy, or extensive comorbidities 4
The American Diabetes Association recommends individualized glycemic goals based on coexisting chronic illnesses, cognitive function, and functional status 6
Safe and moderate glycemic control that minimizes hypoglycemia risk is recommended for elderly patients 5

HbA1c should be measured at least every 6 months if targets are not being met, or every 12 months if stable 4
Self-monitoring of blood glucose should be considered based on functional and cognitive abilities, goals of care, and hypoglycemia risk 4

Overtreatment with intensive glycemic management has been identified as problematic in older adults with complex medical conditions 6
No randomized controlled trials have shown benefits of tight glycemic control on clinical outcomes and quality of life in elderly patients 5
For patients experiencing severe or frequent hypoglycemia, consider referral to diabetes educators, endocrinologists, or diabetologists 4